AMI Asset Management Corp Lowers Position in Insulet Corporation $PODD

AMI Asset Management Corp decreased its stake in Insulet Corporation (NASDAQ:PODD) by 3.2% during the first quarter, Holdings Channel.com reports. The institutional investor owned 150,335 shares of the medical instruments supplier’s stock after selling 4,989 shares during the quarter. Insulet accounts for about 2.0% of AMI Asset Management Corp’s portfolio, making the stock its 24th largest position. AMI Asset Management Corp’s holdings in Insulet were worth $31,546,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Larson Financial Group LLC grew its holdings in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet during the fourth quarter valued at approximately $26,000. DV Equities LLC bought a new stake in shares of Insulet during the 4th quarter valued at about $28,000. Elyxium Wealth LLC bought a new stake in Insulet during the fourth quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new position in shares of Insulet during the 4th quarter valued at $29,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Raymond James Financial set a $216.00 price objective on shares of Insulet in a research note on Monday, June 8th. Piper Sandler decreased their target price on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. Stifel Nicolaus reduced their target price on Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 price objective (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Finally, BTIG Research reduced their target price on Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, May 26th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $238.67.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.36% of the stock is currently owned by insiders.

Insulet Stock Down 0.3%

Shares of NASDAQ:PODD opened at $157.74 on Tuesday. The company has a market capitalization of $10.93 billion, a PE ratio of 36.68, a P/E/G ratio of 1.10 and a beta of 1.13. Insulet Corporation has a twelve month low of $138.79 and a twelve month high of $354.88. The firm has a 50 day simple moving average of $158.22 and a 200-day simple moving average of $219.15. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the prior year, the business earned $1.02 EPS. Insulet’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts predict that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.